北京臻知医学科技

Beijing Zhenzhi Medical Technology is a clinical-stage biotechnology company dedicated to the development of precision cancer immunotherapies. The company leverages its proprietary IM-NEO platform to identify tumor-specific neoantigens and develop next-generation T-cell receptor engineered T-cell (TCR-T) therapies and neoantigen vaccines. Their lead programs target solid tumors with high unmet medical needs, including liver and lung cancers. By integrating advanced bioinformatics with high-throughput screening, Zhenzhi Medical aims to provide personalized treatment solutions that enhance the immune system's ability to recognize and eliminate cancer cells. The company is headquartered in Beijing and maintains state-of-the-art R&D and manufacturing facilities.